McKinsey January 22, 2025
Most top pharma companies derive more than 60 percent of their revenue from therapies for diseases that affect women uniquely, differently, or disproportionately, putting them in a prime position to close the sex- and gender-based health gap.
Nearly half of the global population—and 80 percent of patients in therapeutic areas such as immunology—are women. And yet, treatments are frequently developed without tailored insights for female patients. Too often, researchers have viewed “women’s health” narrowly through the lens of reproductive organs, treated women as “small men” for other conditions, and ignored critical biological differences such as cellular sex (every cell in the body has a sex), hormonal impacts, and genetic factors. Addressing these differences is not just about equity—it drives more...
Today's Sponsors
Today's Sponsor